JW Pharmaceutical is participating in the Statin-Ezetimibe hyperlipidemia complex market, which has more than 600 products in Korea. It is a combination of Livalo (Pitavastatin) and Ezetimibe.

According to industry sources on the 21st, JW Pharmaceutical recently applied for permission for Pitavastatin-Ezetimibe to the MFDS. It was known as Livalozet. It will be the third Livaro series if approved.
Livalo is a product jointly developed by Japan's Kowa and Nissan Chemical, and is being introduced and sold in Korea by JW Pharmaceutical. It received the first product approval in 2005, and since its launch in Korea, it has recorded high performance as an original Statin formulation. The amount of outp